Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet/coagulative activation identify non-alcoholic fatty liver disease among patients with familial combined hyperlipidemia and/or metabolic syndrom (Q47923190)

From Wikidata

Jump to navigation Jump to search

scientific article published on 25 June 2015

Language	Label	Description	Also known as
English	Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet/coagulative activation identify non-alcoholic fatty liver disease among patients with familial combined hyperlipidemia and/or metabolic syndrom	scientific article published on 25 June 2015

Statements

scholarly article

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/26117210

Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet/coagulative activation identify non-alcoholic fatty liver disease among patients with familial combined hyperlipidemia and/or metabolic syndrom (English)

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/26117210

1 reference

based on heuristic

inferred from title

metabolic dysfunction–associated steatotic liver disease

1 reference

based on heuristic

inferred from title

familial combined hyperlipidemia

1 reference

based on heuristic

inferred from title

non-alcoholic fatty liver

1 reference

based on heuristic

inferred from title

Francesca Santilli

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26117210%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Patrizia Blardi

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26117210%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Carlo Scapellato

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26117210%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Monica Bocchia

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26117210%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Gianni Guazzi

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26117210%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Lucia Terzuoli

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26117210%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Antonella Tabucchi

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26117210%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Antonella Silvietti

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26117210%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Benedetta Lucani

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26117210%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Walter Renato Gioffrè

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26117210%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Francesca Scarpini

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26117210%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Francesca Fazio

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26117210%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Giovanni Davì

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26117210%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Luca Puccetti

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26117210%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

publication date

25 June 2015

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/26117210

Vascular Pharmacology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26117210%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

72

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26117210%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

16-24

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26117210%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Liver fat in the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Genetics of familial combined hyperlipidemia and risk of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Genetic influence in liver steatosis prevalence and proatherothrombotic/inflammatory profile in familial combined hyperlipoproteinemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Advanced glycation end products (AGEs) and their involvement in liver disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Soluble forms of RAGE in human diseases: clinical and therapeutical implications

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

What is the role of the receptor for advanced glycation end products-ligand axis in liver injury?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

sRAGE and risk of diabetes, cardiovascular disease, and death

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Small, Dense LDL and Elevated Apolipoprotein B Are the Common Characteristics for the Three Major Lipid Phenotypes of Familial Combined Hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Assessment of liver stiffness in subjects affected by familial combined hyperlipidaemia with hepatic steatosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Determinants of thromboxane biosynthesis in rheumatoid arthritis: Role of RAGE and oxidant stress.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

3'UTR/T polymorphism of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is associated with modified anti-platelet activity of atorvastatin in hypercholesterolemic subjects.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Genetic variation in lectin-like oxidized low-density lipoprotein receptor 1 (LOX1) gene and the risk of coronary artery disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Genetic influence in antithrombotic actions of atorvastatin in hypercholesterolaemia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Cytokines in acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Pro-inflammatory/anti-inflammatory cytokine imbalance in acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Population differences in allele frequencies at theOLR1locus may suggest geographic disparities in cardiovascular risk events

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Allele frequencies of polymorphisms of TNFA, IL-6, IL-10 and IFNG in an Italian Caucasian population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Adiponectin gene polymorphisms and their effect on the risk of myocardial infarction and type 2 diabetes: an association study in an Italian population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Endogenous formation of Nε-(carboxymethyl)lysine is increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic steatosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Dietary glycotoxins exacerbate progression of experimental fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Steatohepatitis: a tale of two "hits"?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

What is the significance of soluble and endogenous secretory receptor for advanced glycation end products in liver steatosis in obese prepubertal children?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Lower serum endogenous secretory receptor for advanced glycation end product level as a risk factor of metabolic syndrome among Japanese adult men: a 2-year longitudinal study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Intrahepatic insulin exposure, intrahepatocellular lipid and regional body fat in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2015.04.004

7 January 2021

Identifiers

10.1016/J.VPH.2015.04.004

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26117210%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26117210%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47923190&oldid=1531211515"